Recruiting
Bladder cancer
RecruitingStudy of EG-70 for Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to BCG or High-Risk Patients New to BCG or with Incomplete BCG Treatment
InvestigationalNo placebo
Study of EG-70 for Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to BCG or High-Risk Patients New to BCG or with Incomplete BCG Treatment
InvestigationalNo placebo
- Disease:Bladder cancer
- Substances:Lauromacrogol 400Detalimogene voraplasmid
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Lauromacrogol 400



